Study Shows Compound Significantly Prevents Progression of Diet-Induced Non-Alcoholic Fatty Liver Disease
Dec 10 2020 Read 580 Times Rom et al report that the oral administration of the simple tri-peptide, DT-109 (Patent US8664177B2), prevents both development of non-alcoholic fatty liver disease (NAFLD) and late stage fibrosis in a murine model of diet-induced non-alcoholic steatohepatitis (NASH). The study titled, ‘Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome’ was published in Science Translational Medicine on 2 December 2020. DT-109 is a 3 amino acid, orally active peptide, that stimulates release of intestina...
Source: labmate-online.com